Abstract
Future studies with daunorubicin involve mainly comparative evaluations with other anthracycline antibiotics and related compounds. Efforts are ongoing to improve the therapeutic index of these drugs. This includes not only laboratory development but also clinical evaluation of analogs, manipulations in dose schedules, and the use of protectors of toxic manifestations, primarily of cardiomyopathy. Technological advances in the clinical area permit, for example, the exploration of daunorubicin and related compounds by continuous infusion under more precise pharmacologic and cardiologic monitoring than was possible when they were initially introduced.
| Original language | English |
|---|---|
| Pages (from-to) | 35-37 |
| Number of pages | 3 |
| Journal | Cancer Treatment Reports |
| Volume | 65 |
| Issue number | Suppl. 4 |
| State | Published - 1981 |
| Externally published | Yes |